DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects

(2013) R Yu et al.   Cell Death & Disease

Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL

(2012) Eva Szegezdi et al.   MOLECULAR & CELLULAR PROTEOMICS

Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5

(2011) Caroline MM van Geelen et al.   BMC CANCER

Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis

(2011) David Vindrieux et al.   Cancer Cell International

IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells

(2011) Chirlei Klein Büneker et al.   CANCER LETTERS

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants

(2011) C R Reis et al.   Cell Death & Disease

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors

(2010) D. Stadel et al.   CLINICAL CANCER RESEARCH

Targeting AML through DR4 with a novel variant of rhTRAIL

(2010) Eva Szegezdi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

(2010) Johannes Lemke et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Unraveling the Binding Mechanism of Trivalent Tumor Necrosis Factor Ligands and Their Receptors

(2010) Carlos R. Reis et al.   MOLECULAR & CELLULAR PROTEOMICS

Targeting of XIAP Combined with Systemic Mesenchymal Stem Cell-Mediated Delivery of sTRAIL Ligand Inhibits Metastatic Growth of Pancreatic Carcinoma Cells

(2010) Andrea Mohr et al.   STEM CELLS

Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors†

(2009) Carlos R. Reis et al.   BIOCHEMISTRY

Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma

(2009) M. Vogler et al.   CANCER RESEARCH

Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer

(2009) M. R. Loebinger et al.   CANCER RESEARCH

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

(2009) E. W. Duiker et al.   CLINICAL CANCER RESEARCH

Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy

(2009) Lata G. Menon et al.   STEM CELLS

Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma

(2008) S. M. Kim et al.   CANCER RESEARCH

Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth In vitro and In vivo

(2008) M. Vogler et al.   CANCER RESEARCH

DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design

(2008) Vicente Tur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model

(2008) Andrea Mohr et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE